Table 2 Input values in the base case analysis
FCM | Placebo | Source | |
|---|---|---|---|
Proportion of patients according to NYHA class at baseline | |||
NYHA class II | 0.17 | 0.19 | Anker 2009 [16] |
NYHA class III | 0.83 | 0.81 | Anker 2009 [16] |
Proportion of patients according to NYHA class at 24 weeks | |||
NYHA class I | 0.06 | 0.01 | Anker 2009 [16] |
NYHA class II | 0.41 | 0.29 | Anker 2009 [16] |
NYHA class III | 0.5 | 0.65 | Anker 2009 [16] |
NYHA class IV | 0.01 | 0.03 | Anker 2009 [16] |
Death | 0.02 | 0.03 | Anker 2009 [16] |
Total medication cost (IDA treatment cost) | US $645 | 0 | |
FCM price (500 mg vial) | US $160 | 0 | Suggested price |
Dose | 1,000 mg | 0 | KNF |
No. of infusions | 2 | 0 | Gutzwiller 2012 [19] |
Normal saline price (200 mL) | US $1.8 | 0 | HIRA weighted price |
Infusion fee | US $1.1 | 0 | NHI fee schedule |
Adjusted CHF medical cost by NYHA class excluding cost of IV iron treatment (6 months) | |||
NYHA class I | US $510 | US $510 | See Table 1 |
NYHA class II | US $928 | US $928 | See Table 1 |
NYHA class III | US $1,623 | US $1,623 | See Table 1 |
NYHA class IV | US $3,142 | US $3,142 | See Table 1 |
Utility weight according to NYHA class (1 year) | |||
NYHA class I | 0.93 | 0.93 | Fox 2007 [21] |
NYHA class II | 0.78 | 0.78 | Fox 2007 [21] |
NYHA class III | 0.61 | 0.61 | Fox 2007 [21] |
NYHA class IV | 0.44 | 0.44 | Fox 2007 [21] |
Utility difference from the FAIR-HF study | 0.037 (scenario 2) | Gutzwiller 2012 [19] | |